AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.

A mere 5 months ago, our world turned upside down when our grandson William was diagnosed with Duchenne muscular dystrophy (DMD). We had been searching for answers, worried about his struggles with ...

The new price transparency tool to compare reimbursement rates.

Apr. 3, 2025 — A new CT-scan based risk score facilitates the identification of patients at risk of revision endoscopic sinus surgery due to chronic ...

Whereas imaging of the cornea and conjunctiva is mainly limited by resolution, imaging of the skin and uvea is limited by penetration. Furthermore, imaging of pigmented and vascularised lesions is ...